Novo Nordisk announced that the European Medicines Agency (EMA) has approved an update to the label for Rybelsus (oral ...

The funding round was boosted by $30m after Reunion’s lead candidate RE104 hit efficacy goals in a Phase II trial.

Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.

Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors to expand its anticoagulation ...

Annual Meeting 2025, held from August 29 to September 1 in Madrid, Spain, showcased a sweeping array of advancements in the cardiovascular and metabolic disorders (CVMD) space, with 7,804 total ...

The deal marks the second time Novartis has tapped Monte Rosa’s services in just under year. The US big pharma company paid ...

AstraZeneca has halted its planned £200m ($270m) investment in a research facility in Cambridge, according to reports from ...

US-based Amneal Pharmaceuticals has secured approval from the FDA for its 500mg/mL sodium oxybate oral solution.

FDA chief Martin Makary said the agency will now ‘proactively monitor’ pharma companies for advertising law breaches.

MSD has scrapped its UK expansion plans due to the government's lack of investment in the life sciences sector.

On this episode, the healthcare editorial team unpicks several key trials and trends from this year’s event, held from 29 ...